Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05113251
Title Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab deruxtecan

Trastuzumab deruxtecan

Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | DEU | CAN | AUT


No variant requirements are available.